Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct

Diarrhoea;Acute Clinical Trial

— TrEAT_TD2  

Official title:

A Randomized Controlled Trial Evaluating Single-dose Rifaximin Versus Azithromycin With Loperamide Adjunct for Treatment of Acute Watery Diarrhea

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05677282
• Other study ID #: IDCRP-115
• Status: Recruiting
• Phase: Phase 4
• Start date: October 28, 2022
• Est. completion date: December 2024

Study information

• Verified date: December 2023
• Source: Henry M. Jackson Foundation for the Advancement of Military Medicine
• Contact: Principal Investigator
• Phone: 240-855-6584
• Email: contactus[@]idcrp.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare a single dose of rifaximin with loperamide to the current standard approach of single dose azithromycin with loperamide for the treatment of acute watery traveler's diarrhea (TD).

The study requires 1) taking a single dose antibiotic plus loperamide to treat TD, 2) providing blood and stool samples at different time points to evaluate infection and immune responses, 3) completing a daily symptom diary following treatment, 4) being seen by the study doctor to monitor illness and recovery, and 5) completing a brief electronic questionnaire at 3 months.

Participants will be randomly assigned to one of the two treatment groups. The two groups are 1) rifaximin 550 mg as a single dose with loperamide 4 mg initially followed by 2 mg after each unformed stool or 2) azithromycin 500 mg as a single dose with loperamide 4 mg initially followed by 2 mg after each unformed stool. Both groups will take the antibiotic dose and 4 mg of loperamide.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Active duty military, 18-60 years old

2. Presence of acute watery diarrhea (3 or more loose/liquid stools in 24 hours or 2 loose/liquid stools in 24 hours and associated symptoms such as nausea, vomiting, abdominal cramps or tenesmus) lasting <96 hours in duration that impacts function in activities and/or performance of primary duties. Refer to recruitment decision tree below.

3. Eligible for ambulatory management. (Note: Ambulatory management in this study means that the patient can be treated on an outpatient basis to include up to 23 hours of medical observation and IV therapies.)

4. Able to comply with follow-up procedures.

5. Will remain in country for at least 7 days or an assurance that follow-up can be arranged elsewhere.

Exclusion Criteria:

1. Allergy to rifamycins, macrolides, or loperamide (not including mild gastrointestinal upset).

2. Antibiotic therapy in the 72 hours prior to presentation (excluding malaria prophylaxis with mefloquine, malarone, chloroquine/proguanil, tafenoquine, or doxycycline).

3. Concomitant medications with known drug-drug interactions with any of the study drugs (includes theophylline, digoxin, warfarin, chloroquine and hydroxychloroquine).

4. Current or history of liver disease or other serious health conditions based on review by study physician.

5. Acute dysentery and/or febrile illness (temperature > 100.4°F [38.1°C]).

6. Presence of symptoms >96 hours prior to initiating treatment.

7. Use of >4 mg loperamide or use of any amount of loperamide for greater than 24 hours prior to enrollment. Prior use of bismuth subsalicylate or other anti-diarrheal, non-antibiotic therapy in the 48 hours prior to enrollment.

8. Positive pregnancy test at presentation (unknown effects with rifaximin). All female participants will be administered a urine pregnancy test prior to enrollment.

9. Previously screened or randomized in this study.

Related Conditions & MeSH terms

• Diarrhea
• Diarrhea Travelers
• Diarrhoea;Acute

Intervention

Drug:
• Rifaximin 550 MG
Rifaximin 550 mg as a single dose administered orally.
• Azithromycin 500 MG
Azithromycin 500 mg as a single dose administered orally.
• Loperamide
4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).

Locations

Country	Name	City	State
Djibouti	Camp Lemonnier Djibouti	Djibouti
Honduras	JTF-Bravo, Soto Cano AB	Comayagua
Kenya	British Army Training Site UK	Nanyuki

Sponsors (3)

Lead Sponsor	Collaborator
Henry M. Jackson Foundation for the Advancement of Military Medicine	Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences

Countries where clinical trial is conducted

Djibouti,  Honduras,  Kenya, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Therapeutic efficacy of single-dose rifaximin (550 mg) with loperamide in treating acute watery diarrhea compared to single-dose azithromycin (500 mg) with loperamide.	Time to last unformed stool (TLUS), in hours, is calculated from the time of antibiotic dose to last unformed (diarrheal) stool (TLUS).	Up to 1 week (up to 168 hours)
Secondary	Proportion of participants no longer meeting TD illness criteria at 24 hours	The clinical efficacy cure rate at 24h is the proportion of participants at the 24h follow up after the initial treatment who met the end point of not meeting TD illness.	24 hours
Secondary	Proportion of participants no longer meeting TD illness criteria at 72 hours	For the clinical efficacy cure rate at 72h is the proportions of participants who met the end point; no report of unformed/diarrheal/loose/liquid stool (LLS) that meet TD illness >24h after initial treatment and; TD-associated symptoms present at 24h were not reported as moderate or greater	72 hours
Secondary	Proportion of participants with recurrence of TD illness after previous resolution of TD illness	TD recurrence at 7d follow up if participants meet TD illness and had the previous cure resolution at 24h or 72h	7 days
Secondary	Proportions of serious adverse events (SAE) at 21 days	Proportions of serious adverse events (SAE)	21 days